AXON Stock Analysis: Axon Enterprise | NASDAQ
Aerospace & Defense | NASDAQ, USA | Market Cap: 50.163m USD | 12M Return: -20.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 534M
EPS Trend: 97.2%
Qual. Beats: 0
Rev. Trend: 100.0%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Axon Enterprise (NASDAQ: AXON) is a Scottsdale, Arizona-based public safety technology company that operates two business segments: Software and Services, and Connected Devices. The Software and Services segment delivers cloud-based SaaS platforms for capturing, storing, managing, and analyzing video and digital evidence, with products including Axon Evidence, Draft One, Axon Records, Axon Standards, and Axon Fusus. The Connected Devices segment produces integrated hardware such as TASER conducted energy devices, body-worn and in-car cameras, drone and counter-drone systems, and virtual reality training equipment. Customers span federal, state, and local law enforcement agencies, international governments, commercial enterprises, and consumers, reached through direct sales, distributors, and resellers.
The company, founded in 1993 and formerly known as TASER International, rebranded to Axon in April 2017 to reflect its evolution from a hardware-only stun-gun maker into a dual-segment platform combining recurring software subscriptions with device sales. Classified within the Industrials sector under Aerospace & Defense per GICS, Axon is considered a large-cap stock, and its evidence-management platform is built on a SaaS business model that creates recurring revenue and customer stickiness through stored digital evidence and integrated device-software workflows.
- Draft One AI software expands recurring revenue margins
- Body camera and cloud ARR scales double digits
- Motorola Solutions competition pressures public safety contracts
| Net Income: 206.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -5.68 > 1.0 |
| NWC/Revenue: 51.48% < 20% (prev 109.6%; Δ -58.12% < -1%) |
| CFO/TA 0.02 > 3% & CFO 154.0m > Net Income 206.2m |
| Net Debt (1.21b) to EBITDA (386.2m): 3.12 < 3 |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.5m) vs 12m ago 1.22% < -2% |
| Gross Margin: 59.32% > 18% (prev 60.57%; Δ -1.25% > 0.5%) |
| Asset Turnover: 45.37% > 50% (prev 36.60%; Δ 8.78% > 0%) |
| Interest Coverage Ratio: 2.58 > 6 (EBIT TTM 297.1m / Interest Expense TTM 115.1m) |
| A: 0.22 (Total Current Assets 2.74b - Total Current Liabilities 1.21b) / Total Assets 7.07b |
| B: 0.16 (Retained Earnings 1.11b / Total Assets 7.07b) |
| C: 0.05 (EBIT TTM 297.1m / Avg Total Assets 6.58b) |
| D: 1.00 (Book Value of Equity 3.53b / Total Liabilities 3.53b) |
| Altman-Z'' = 3.29 = A |
| DSRI: 0.67 (Receivables 870.3m/974.1m, Revenue 2.98b/2.23b) |
| GMI: 1.02 (GM 60.57% / 59.32%) |
| AQI: 1.68 (AQ_t 0.56 / AQ_t-1 0.34) |
| SGI: 1.34 (Revenue 2.98b / 2.23b) |
| TATA: 0.01 (NI 206.2m - CFO 154.0m) / TA 7.07b) |
| Beneish M = -2.64 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 640.46 with a total of 1,685,162 shares traded. Over the past week, the price has changed by +25.43%, over one month by +35.96%, over three months by +71.76% and over the past year by -20.16%.
Current recommended Stop Loss: 604.20 (which is 5.7% or 1.1 ATR below the current price).
Axon Enterprise has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy AXON.
- StrongBuy: 7
- Buy: 7
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 662 | 3.4% |
P/E Trailing = 247.9482
P/E Forward = 74.0741
P/S = 16.8148
P/B = 13.6166
P/EG = 1.6448
Revenue TTM = 2.98b USD
EBIT TTM = 297.1m USD
EBITDA TTM = 386.2m USD
Long Term Debt = 1.73b USD (from longTermDebt, last quarter)
Short Term Debt = 80.6m USD (from shortTermDebt, last fiscal year)
Debt = 1.93b USD (from shortLongTermDebtTotal, last quarter) + Leases 97.2m
Net Debt = 1.21b USD (calculated: Debt 1.93b - CCE 718.9m)
Enterprise Value = 51.4b USD (50.2b + Debt 1.93b - CCE 718.9m)
Interest Coverage Ratio = 2.58 (Ebit TTM 297.1m / Interest Expense TTM 115.1m)
EV/FCF = 1000.0x (Enterprise Value 51.4b / FCF TTM 19.5m)
FCF Yield = 0.04% (FCF TTM 19.5m / Enterprise Value 51.4b)
FCF Margin = 0.65% (FCF TTM 19.5m / Revenue TTM 2.98b)
Net Margin = 6.91% (Net Income TTM 206.2m / Revenue TTM 2.98b)
Gross Margin = 59.32% ((Revenue TTM 2.98b - Cost of Revenue TTM 1.21b) / Revenue TTM)
Gross Margin QoQ = 59.12% (prev 57.90%)
Tobins Q-Ratio = 7.27 (Enterprise Value 51.4b / Total Assets 7.07b)
Interest Expense / Debt = 5.98% (Interest Expense 115.1m / Debt 1.93b)
Taxrate = 15.44% (30.9m / 200.2m)
NOPAT = 251.2m (EBIT 297.1m * (1 - 15.44%))
Current Ratio = 2.27 (Total Current Assets 2.74b / Total Current Liabilities 1.21b)
Debt / Equity = 0.54 (Debt 1.93b / totalStockholderEquity, last quarter 3.53b)
Debt / EBITDA = 3.12 (Net Debt 1.21b / EBITDA 386.2m)
Debt / FCF = 61.85 (Net Debt 1.21b / FCF TTM 19.5m)
Total Stockholder Equity = 3.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.14% (Net Income 206.2m / Total Assets 7.07b)
RoE = 6.58% (Net Income TTM 206.2m / Total Stockholder Equity 3.13b)
RoCE = 6.11% (EBIT 297.1m / Capital Employed (Equity 3.13b + L.T.Debt 1.73b))
RoIC = 4.34% (NOPAT 251.2m / Invested Capital 5.79b)
WACC = 8.95% (E(50.2b)/V(52.1b) * Re(9.10%) + D(1.93b)/V(52.1b) * Rd(5.98%) * (1-Tc(0.15)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 3.59%
[DCF] Terminal Value 70.88% ; FCFF base≈156.7m ; Y1≈137.5m ; Y5≈111.1m
[DCF] Fair Price = 5.15 (EV 1.62b - Net Debt 1.21b = Equity 415.5m / Shares 80.6m; r=8.95% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 97.23 | EPS CAGR: 33.86% | SUE: 0.03 | # QB: 0
Revenue Correlation: 99.99 | Revenue CAGR: 32.78% | SUE: 2.40 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.83 | Chg30d=+0.00% | Revisions=+10% | Analysts=18
EPS next Quarter (2026-09-30): EPS=2.02 | Chg30d=+0.00% | Revisions=-5% | Analysts=18
EPS current Year (2026-12-31): EPS=7.69 | Chg30d=+0.00% | Revisions=+5% | GrowthEPS=+12.2% | GrowthRev=+31.5%
EPS next Year (2027-12-31): EPS=10.57 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=+37.5% | GrowthRev=+29.3%
[Analyst] Revisions Ratio: +11% (up=40, down=32)